BRIEF-Tscan Therapeutics Announces Positive Initial Data From Phase 1 Study In Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

TCRX

0.00

June 22 (Reuters) - TScan Therapeutics Inc TCRX.O:

  • TSCAN THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM COHORT C OF ONGOING ALLOHA™ PHASE 1 STUDY EVALUATING TSC-101 IN PATIENTS WITH HEME MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  • TSCAN THERAPEUTICS - TSC-101 CONTINUES TO BE WELL-TOLERATED

  • TSCAN THERAPEUTICS - ON TRACK TO ENROLL FIRST PATIENT IN PHASE 3 ALLOHA-2 STUDY OF TSC-101 THIS MONTH

Source text: ID:nGNX11tWRq

Further company coverage: TCRX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.